| Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? A Fountas, LN Diamantopoulos, A Tsatsoulis Trends in Endocrinology & Metabolism 26 (11), 643-656, 2015 | 104 | 2015 |
| Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, MA Bilen, V Santos, J Esther, ... Cancer 126 (6), 1208-1216, 2020 | 79 | 2020 |
| Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors D Michailidou, AR Khaki, MP Morelli, L Diamantopoulos, N Singh, ... Scientific reports 11 (1), 9029, 2021 | 53 | 2021 |
| A new prognostic model in patients with advanced urothelial carcinoma treated with first-line immune checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, NJ Miller, L Carril-Ajuria, ... European urology oncology 4 (3), 464-472, 2021 | 46 | 2021 |
| Histological subtypes and response to PD-1/PD-L1 blockade in advanced urothelial cancer: a retrospective study NJ Miller, AR Khaki, LN Diamantopoulos, MA Bilen, V Santos, N Agarwal, ... The Journal of urology 204 (1), 63-70, 2020 | 38 | 2020 |
| Prognostic factors for survival among patients with small bowel neuroendocrine tumours associated with mesenteric desmoplasia FM Laskaratos, L Diamantopoulos, M Walker, H Walton, M Khalifa, ... Neuroendocrinology 106 (4), 366-380, 2018 | 28 | 2018 |
| Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes LN Diamantopoulos, AR Khaki, P Grivas, JL Gore, GR Schade, AC Hsieh, ... Bladder Cancer 6 (1), 71-81, 2020 | 24 | 2020 |
| Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes SM Esagian, AR Khaki, LN Diamantopoulos, L Carril‐Ajuria, D Castellano, ... BJU international 128 (2), 196-205, 2021 | 22 | 2021 |
| Antiproliferative effect of above-label doses of somatostatin analogs for the management of gastroenteropancreatic neuroendocrine tumors LN Diamantopoulos, FM Laskaratos, M Kalligeros, R Shah, ... Neuroendocrinology 111 (7), 650-659, 2021 | 18 | 2021 |
| Safety of immunizations for the adult patient with inflammatory bowel disease—a systematic review and meta-analysis A Desalermos, M Pimienta, M Kalligeros, F Shehadeh, L Diamantopoulos, ... Inflammatory Bowel Diseases 28 (9), 1430-1442, 2022 | 17 | 2022 |
| Response to neoadjuvant chemotherapy and survival in micropapillary urothelial carcinoma: data from a tertiary referral center and the surveillance, epidemiology, and end … LN Diamantopoulos, SK Holt, AR Khaki, RR Sekar, A Gadzinski, ... Clinical genitourinary cancer 19 (2), 144-154, 2021 | 14 | 2021 |
| Central nervous system metastasis in patients with urothelial carcinoma: institutional experience and a comprehensive review of the literature LN Diamantopoulos, AR Khaki, GP Sonpavde, VA Venur, YY Evan, ... Clinical genitourinary cancer 18 (3), e266-e276, 2020 | 14 | 2020 |
| Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration P Ravi, GR Pond, LN Diamantopoulos, C Su, A Alva, RK Jain, ... BJU international 128 (5), 607-614, 2021 | 12 | 2021 |
| Treatment rechallenge with immune checkpoint inhibitors in advanced urothelial carcinoma D Makrakis, DR Bakaloudi, R Talukder, GI Lin, LN Diamantopoulos, ... Clinical genitourinary cancer 21 (2), 286-294, 2023 | 11 | 2023 |
| Association between sites of metastasis and outcomes with immune checkpoint inhibitors in advanced urothelial carcinoma D Makrakis, R Talukder, GI Lin, LN Diamantopoulos, S Dawsey, S Gupta, ... Clinical genitourinary cancer 20 (5), e440-e452, 2022 | 11 | 2022 |
| Biomarkers in small intestine NETs and carcinoid heart disease: a comprehensive review M Kalligeros, L Diamantopoulos, C Toumpanakis Biology 10 (10), 950, 2021 | 11 | 2021 |
| Sarcomatoid urothelial carcinoma: a population-based study of clinicopathologic characteristics and survival outcomes LN Diamantopoulos, D Korentzelos, M Alevizakos, JL Wright, P Grivas, ... Clinical Genitourinary Cancer 20 (2), 139-147, 2022 | 10 | 2022 |
| Patterns and timing of perioperative blood transfusion and association with outcomes after radical cystectomy LN Diamantopoulos, RR Sekar, SK Holt, AR Khaki, NJ Miller, A Gadzinski, ... Urologic Oncology: Seminars and Original Investigations 39 (8), 496. e1-496. e8, 2021 | 9 | 2021 |
| Bladder cancer multidisciplinary clinic (BCMC) model influences disease assessment and impacts treatment recommendations LN Diamantopoulos, BR Winters, P Grivas, SD Ngo, J Zeng, AC Hsieh, ... Bladder Cancer 5 (4), 289-298, 2019 | 8 | 2019 |
| Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC):“Real world” experience DR Bakaloudi, R Talukder, GI Lin, D Makrakis, LN Diamantopoulos, ... Clinical genitourinary cancer 21 (5), 584-593, 2023 | 6 | 2023 |
